MDT-AP-0580
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 38.04
- os_event
- false
- age_years
- 7.72
- sex
- M
- new_clusters
- C3
- umap1_2d
- 3.031843176
- umap2_2d
- 2.216757268
- umap1_3d
- 0.366945174
- umap2_3d
- -2.834712264
- umap3_3d
- -2.813528287
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UNFOLDED_PROTEIN_RESPONSE+0.480
- MYC_TARGETS_V2+0.390
- DNA_REPAIR+0.370
- HEDGEHOG_SIGNALING+0.350
- MYC_TARGETS_V1+0.310
- OXIDATIVE_PHOSPHORYLATION+0.280
- MTORC1_SIGNALING+0.260
- FATTY_ACID_METABOLISM+0.210
- GLYCOLYSIS+0.210
- PANCREAS_BETA_CELLS+0.190
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.510
- INTERFERON_GAMMA_RESPONSE-0.460
- ALLOGRAFT_REJECTION-0.440
- IL6_JAK_STAT3_SIGNALING-0.350
- INFLAMMATORY_RESPONSE-0.350
- IL2_STAT5_SIGNALING-0.280
- COMPLEMENT-0.240
- NOTCH_SIGNALING-0.220
- APICAL_SURFACE-0.210
- TNFA_SIGNALING_VIA_NFKB-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-NK-A5CR-01A-11R-A26W-07 | — | cohortSQ2 | 0.860 |
| 2 | MDT-AP-0756 | Med | Medulloblastoma | 0.850 |
| 3 | TCGA-60-2722-01A-01R-0851-07 | — | cohortSQ2 | 0.843 |
| 4 | BS_YETBN0RQ | Med | Medulloblastoma | 0.829 |
| 5 | 87F9E756-60BB-435B-9A2D-211E89C182D9 | — | — | 0.824 |
| 6 | SRR6013533 | — | cohortSQ2 | 0.823 |
| 7 | TCGA-CV-6962-01A-11R-1915-07 | — | — | 0.823 |
| 8 | ccfdc2a2-bb01-41c2-9ef1-98bbd1cfae22 | — | — | 0.820 |
| 9 | TCGA-33-AAS8-01A-11R-A405-07 | — | cohortSQ2 | 0.812 |
| 10 | 0A4681EC-A57A-45CD-BB97-3E90A8CDECDD | — | — | 0.809 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UNFOLDED_PROTEIN_RESPONSE | 0.480 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.390 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.370 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.350 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.310 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.280 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.260 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.210 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.190 | Cobimetinib | — uncovered |
| PEROXISOME | 0.190 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.190 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.180 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.170 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.160 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.150 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.150 | Temsirolimus | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.120 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.110 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.100 | Inavolisib | — uncovered |